John Theurer Cancer Center Leading Urologist Presents Research Abstracts at American Urological Association's 2010 Annual Meeting

Jun 02, 2010, 15:30 ET from John Theurer Cancer Center

HACKENSACK, N.J., June 2 /PRNewswire/ -- Ihor S. Sawczuk, M.D., Co-Chief of the Division of Urologic Oncology at John Theurer Cancer Center at Hackensack University Medical Center, internationally recognized for his work in urologic oncology, will be among physicians from the Cancer Center presenting research abstracts at the American Urological Association's 2010 Annual Meeting.  

The American Urological Association (AUA) is committed to fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients.  The AUA's Annual Meeting is the world's foremost meeting of urologists, joining nearly 11,000 practicing physicians and healthcare professionals at the largest gathering of urological professionals worldwide.

Dr. Sawczuk is a leading authority on renal (kidney) cancer and the various methods used to treat it, including laparoscopic radical and partial nephrectomy (removal of all or part of a kidney), immunological management using cancer vaccines, laparoscopic cryoablation, and nephron-sparing kidney surgery.  In the field of prostate cancer, Dr. Sawczuk and his colleagues in the Division of Urologic Oncology have been delivering tremendous outcomes for many years, as evidenced by achieving an astounding 95 percent usage rate in 2005 with robotic-assisted radical prostatectomy to treat localized prostate cancer, when the national rate was only 20 percent.  These results continue through today: the department was recently rated as the top prostate cancer treatment center in New Jersey by Healthgrades for their outcomes.

The abstracts John Theurer Cancer Center will present focus on the following topics: laparoscopic adrenalectomy (horseshoe kidney), hypogonadal patients receiving clomiphene citrate or anastrozole for infertility, robot-assisted radical prostatectomy and CT-fused indium-111 capromab pendetide immunoscintigraphy in management of recurrent prostate cancer.

Jennifer Yates, M.D. and Ravi Munver, vice chairman and chief of minimally invasive and robotic urologic surgery for the Department of Urology, were collaborators on these projects.

"The John Theurer Cancer Center's mission is to deliver extraordinary cancer care," said Andrew L. Pecora, M.D., Chairman and Executive Administrative Director, John Theurer Cancer Center.  "Dr. Sawczuk and the physicians in our Division of Urologic Oncology are among the very best doctors and researchers.  We applaud them for continuing their national leadership in the field of urology."

The Division of Urologic Oncology at the John Theurer Cancer Center specializes in the diagnosis, treatment, and management of all types of urologic malignancies, including cancers of the prostate, kidney, bladder, testes, penis, ureters, urethra, and adrenal glands. This multidisciplinary team is highly skilled in the most advanced diagnostic and treatment methods available today to fight urologic cancers, including minimally invasive, laparoscopic, and robotic surgical procedures and cryosurgery. They work closely with radiation oncologists, medical oncologists, and other cancer specialists to provide optimal care for patients.  

About the John Theurer Cancer Center at Hackensack University Medical Center: The John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancer. The 15 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, the John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of after care services that distinguish the John Theurer Cancer Center from other facilities.

SOURCE John Theurer Cancer Center